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Summary: Recently CYFRA 21-1, a new tumour marker measuring a fragment of cytokeratin 19, was
introduced (1,2) and proved to be suitable for the follow-up care and monitoring of the therapy of non-small
cell lung carcinomas, especially squamous cell carcinomas of the lung (3, 4). Besides CYFRA 21-1, there are
two other tumour markers available, called tissue polypeptide antigen (TPA) and tissue polypeptide specific
antigen (TPS), which also measure different cytokeratins in serum. In a retrospective study we investigated
the clinical significance of these 3 cytokeratin markers in lung cancer compared with carcinoembryonic antigen
(CEA), squamous cell carcinoma antigen (SCC) and neuron-specific enolase (NSE). We investigated the sera
of 50 healthy persons, 273 patients with various benign diseases and 218 patients with histologically proven
lung cancer. In a first step the specificity versus benign diseases of the lung was established for all the markers,
and was fixed at 95%. Then the single and combined sensitivities were calculated. CYFRA 21-1 proved to
possess the highest sensitivity in lung cancer in general (61%), in non-small cell lung carcinomas (64%), in
squamous cell carcinomas (79%), in adenocarcinomas (54%) and in large cell carcinomas (65%). In small
cell lung carcinomas, neuron-specific enolase proved again to be the marker of first choice (55%). Combined
determinations proved clearly increased sensitivity only for large cell carcinomas (CYFRA 21-1 + TPA: 77%)
and for small cell lung carcinomas (CYFRA 21-1 + NSE: 62%). From our investigations it was evident that
TPA detects at least partly the same substance as CYFRA 21-1 (the sensitivities compared with the markers
TPS, CEA, SCC and NSE were rather high, but not as high as for CYFRA 21-1), whereas the TPS assay
measures a completely different clinical chemical analyte (lowest number of true positive test results over the
whole investigation). These findings correspond cleary to the very recent results of the comparison of CYFRA
21-1, TPA and TPS by immunoblotting (5).
Introduction _ ,, , ^.r-r-,^ * ~ *Recently a new tumour marker, called CYFRA 21-1,
In many industrialized countries, lung cancer is the was described for the detection of cytokeratin 19-
inost common cancer in men and is climbing quickly fragments in serum (1, 2). Cytokeratins and other
toward the same incidence in women. Clinical chem- intermediate filaments of the cell like vimentin and
ical methods for the support of adequate follow up desmin have become well known since the develop-
care and the control of efficiency of therapy are avail- ment of monoclonal antibodies in histopathology for
able only for small cell lung carcinomas, and they the differentiation and classification of physiological
consist of the determination of neuron specific enolase and pathological tissues (8, 9). The expression of a
(6, 7). single cytokeratin or a combination of certain cyto-
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keratins is typical for defined tissues, for example
cytokeratin 7 and 8 in the epithelium of the trachea
and urothelium. In contrast to cytokeratins them-
selves, fragments of intermediate filaments are soluble
in serum and can therefore be detected and measured
with the aid of monoclonal antibodies. Since cyto-
keratin 19 is particulary abundant in carcinoma of
the lung (10, 11), the assay CYFRA 21-1, combining
two monoclonal antibodies directed specifically
against this cytokeratin, was developed (1, 2).
According to our own investigations, (3, 4) and the
results of a European multicentre study, CYFRA 21-1
shows a good specificity-sentitivity-profile in lung
cancer and is suitable for diagnosis, control of therapy
efficiency and follow up care of patients with non-
small cell lung carcinoma, especially squamous cell
carcinomas of the lung. TPA and TPS are two other
tumour markers, which represent different cytokera-
tins in serum. In the present investigation we com-
pared the presence of CYFRA 21-1, TPA and TPS
in various benign diseases and their significance in
lung cancer.
Patients
Two reference groups were investigated: 50 persons who were
normal according to clinical examination, and showed no ab-
normal serum values of clinical chemical analytes; and 273
patients with various benign disorders including 58 patients
with benign diseases of the lung (tuberculosis, sarcoidosis, as-
pergillosis, pneumonia, chronic obstruction, hamartoma), 46
with benign diseases of the gastrointestinal tract (liver cirrhosis,
hepatitis, pancreatitis, primary biliary cirrhosis, colitis uicerosa,
Crohn's disease), 30 women with benign disorders of the breast
(mastopathia stage I, II, III, fibroadenoma, galactorrhoe), 73
patients with benign urological diseases (stones, urinary infec-
tions), 31 patients with chronic or acute renal failure and 30
patients with benign gynaecological diseases. As tumour pa-
tients we investigated the sera of 218 patients with histologically
proven lung cancer (62 small cell, 67 adeno, 66 squamous cell,
17 large cell and 6 undifferenciated); all of them were collected
at an active stage of disease (primary diagnosis or recurrent
disease). As this study was done retrospectively, the sera were
stored at — 70 °C in our serum bank.
Methods
The CYFRA 21-1 concentrations were determined by using the
two-step-sandwich Enzymun^-assay (Boehringer Mannheim,
Germany) on the automated test system ES600. TPA values
were determined with the IRMA of Sangtec Medicals (Sweden)
and TPS values with the IRMA of Beki Diagnostics (Sweden).
For the CEA and SCC values we used the enzyme imraimo-
assays on the IMx (automated test system, Abbott, USA) and
for the neuron-specific enolase determinations the radioimmu-
noassay from Pharmacia (Sweden).
Results
Correlation of CYFRA 21-1, TPA and TPS
The coefficients of correlation for all sera investigated
were r = 0.77 for CYFRA 21-1 & TPA, r = 0.41 for
CYFRA 21-1 & TPS arid r = 0.65 for TPA & TPS;
for the reference groups we obtained r = 0.6 for CY-
FRA 21-1 & TPA, r = 0.36 for CYFRA 21-1 & TPS,
and r = 0.76 for TPA & TPS. In squamous cell car-
cinomas of the lung the coefficients of correlation of
CYFRA 21-1 & TPA was r = 0.83, of CYFRA 21-1
& TPS r = 0.36, and of TPA & TPS r = 0.49. "
Diagnostic specificity
In order to compare our results for the different
tumour markers under the same conditions we fol-
lowed the recommendations of the "Hamburger
group for the standardization of tumour markers"
(12) and fixed the cut off values for each reference
group at a specificity of 95%. This basic postulation
resulted in many different cut off-values (tab. 1). In
95% of the normal healthy controls, CYFRA 21-1-
values were then below 1.8 μg/l, TPA-values were
below 133 U/l and TPS-values were below 97 U/l. In
patients with benign diseases of the lung the cut off
changed to a small extent for CYFRA 21-1 (2.1 μg/l)
and for TPA (131 U/l), and to a greater extent for
TPS (237 U/l).
Higher cut off values were necessary in benign diseases
of the gastrointestinal tract: CYFRA 21-1: 5.2
TPA: 713 U/l; TPS: 2021 U/l.
Tab. 1. Cut off values of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific
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In 95% of benign gynaecological disorders, tumour
marker concentrations were below the following cut
off values: CYFRA 21-1: 3.9 μg/l, TPA: 195 U/l, TPS:
214 U/l.
Women with masthopathia and other benign diseases
of the mammary gland proved to have rather low
CYFRA 21-1 -concentrations (95% cut off 1.3 μg/l);
for TPA we obtained a cut off of 243 U/l and for
TPS 226 U/l.
In benign urological disorders without remarkable
renal failure 95% of the patients showed CYFRA 21-
1 -values below 2.6 μ§/1, TPA-values below 165 U/l
and TPS-values below 144 U/l.
In patients with acute or chronic renal failure (with
or without haemodialysis) higher cut off-values had
to be taken to obtain a 95% specificity: CYFRA 21-












Fig. 1. Distribution of the values of cytokeratin fragment 19
(CYFRA 21-1), tissue polypeptide antigen (TPA) and
tissue polypeptide specific antigen (TPS) in lung cancer
regardless of the histological type.
The scale is equalized by dividing the values by the cut
off at 95% specificity versus benign lung diseases.
Diagnostic sensitivity
To examine the clinical potential of CYFRA 21-1,
TPA, TPS, CEA, SCC and NSE we compared the
true positive test results based on a 95% specificity
versus the clinically relevant reference group, in this
case benign diseases of the lung. In these benign
pulmonary disorders the cut off (at a specificity of
95%) value of CYFRA 21-1 was 2.1 μg/l, of TPA 131
U/l, of TPS 237 U/l, of CEA 7.4 μg/l, of SCC 2.4
μg/l and of NSE 18 μg/l. The distribution of the
CYFRA 21-1, TPA and TPS concentrations at the
above mentioned cut off values is shown in figure 1.
Independent of the histological type and with 61 %
true positive test results CYFRA 21-1 showed a
clearly higher sensitivity in lung cancer than the other
markers: TPA (51%), TPS (22%), CEA (29%), SCC
(18%) and NSE (19%) (tab. 2). This high sensitivity
could not be markedly increased by any of the differ-
ent forms of combinations shown in table 3.
If the different carcinomas of the lung are classified
according to their histological type (tab. 2), CYFRA
21-1, with 64% true positive test results, possessed
the highest sensitivity for all non-small cell lung car-
cinomas, followed by TPA (50%), CEA (33%), SCC
(19%) and TPS (17%). Again, no combination of
tests (tab. 3) significantly increased the number of
true positive test results.
In agreement with our pilot study (9), CYFRA 21-1
showed high diagnostic sensitivity (79%) for squa-
mous cell carcinomas of the lung (tab. 2). Correspond-
ing values for other tests were: TPA (62%), SCC
(38%), TPS (18%) and CEA (25%). This good profile
of specificity and sensitivity of CYFRA 21-1 is il-
lustred by the receiver operating characteristic curves
in figure 2. The number of true positive test results
of the different tumour marker combinations was
inferior to those achieved by the single determination
of CYFRA 21-1.
Tab. 2. Sensitivity (%) of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA), tissue polypeptide specific
antigen (TPS), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and neuron specific enolase
(NSE) in lung cancer following the histological classification.
The cut off values were fixed at a specificity of 95% versus benign lung diseases: CYFRA 21-1: 2.1 μ§/1; TPA: 131 U/l;
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Tab 3 Sensitivity of the combinations of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA), tissue
' polypeptide specific antigen (TPS), carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC) and neuron
specific enolase (NSE) in lung cancer at a specificity of 95% versus benign diseases of the lung. For the calculations both
markers combined had to fulfil the specificity of 95% and at least one of them had to show a true positive test result.
Tumour Lung cancer
All Non-small
Marker n = 218 n = 156
CYFRA 21-1 or TPS 54
CYFRA 21-1 or TPA 63
CYFRA 21-1 or CEA 54
CYFRA 21-1 or SCC 51
CYFRA 21-1 or NSE 56
TPS or TPA 31
TPS or CEA 39
TPS or SCC 30
TPS or NSE 28
TPA or CEA 56
TPA or SCC 60
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Fig. 2. Receiver operating characteristic curve
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cell Squamous Adeno Large cell Small cell
n = 66 n = 67 n = 17 n = 62
71 46 53 47
76 55 77 55
60 55 52 40
67 44 44 35
60 45 54 62
33 22 35 37
30 38 35 40
40 19 23 34
18 18 23 53
63 53 41 56
76 49 47 56
62 42 47 64
In adenocarcinomas of the lung (tab. 2) the sensitivity
of CYFRA 21-1 was 54% (TPA 40%, CEA 41%,
TPS 16% and SCC 5%). None of the combinations
could improve this diagnostic sensitivity.
CYFRA 21-1 also showed the best specificity-sensi-
tivity profile in large cell carcinomas of the lung, with
65% true positive test results (TPA 41%, TPS 18%,
CEA 27%, SCC1%).
In small cell lung carcinomas the diagnostic sensitivity
of CYFRA 21-1 was about 52%, while NSE showed
a true positive test result in 55% of the cases (TPA
52%, TPS 32%, CEA 18%, SCC 6%)., This high
sensitivity could be slightly increased to 62% only by
combining CYFRA 21-1 with NSE.
For all non-small cell lung carcinomas the sensitivities
were also calculated following tumour size and tum-
our stages (tab. 4). For CYFRA 21-1 we found a
clear correlation both with tumour size (Tl: 15%, T4:
55%) and tumour stage (stage I: 29%, stage IV: 63%).
Concerning tumour size there was no correlation for
Tab. 4. Sensitivity of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA), tissue polypeptide specific antigen
(TPS), carcinoembryonic antigen (CEA) and squamous cell carcinoma antigen (SCC) in lung cancer, depending on tumour
size and tumour stage.
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TPA (Tl: 4%, T4: 0%) and also none for TPS (Tl:
4%, T4: 0%). CEA proved to have a good correlation
(Tl: 11%, T4: 54%) and to a lower extent also SCC
(Tl: 7%, T4: 36%).
TPA and TPS again proved to be independent of the
extent of disease, as their sensitivities were almost the
same for stage II (TPA: 55%, TPS: 23%) and stage
IV (TPA: 46%, TPS 18%). The CEA-values were
clearly dependent on tumour stages (stage I: 15%,
stage IV: 57%), whereas the number of true positive
SCC-results showed no correlation (stage I: 19%,
stage IV: 22%).
Discussion
Like most the other tumour markers, cytokeratins are
not organ specific and therefore can be expressed in
all human tissues. We compared the expression of the
"cytokeratin markers" CYFRA 21-1, TPA and TPS
in various benign diseases before addressing the main
question of this investigation concerning their clinical
significance in lung cancer. Because we fixed the dif-
ferent specificities at a level of 95%, we obtained, for
most of the different reference groups investigated,
significantly higher cut off values than those normally
used in routine laboratories (tab. 1). This fact of
course results in fewer true positive test results and
therefore in a lower diagnostic sensitivity. Compared
with the marker values obtained for the healthy con-
trol group, the cut off values necessary for a specificity
of 95% in benign diseases of the lung (tab. 1) did not
clearly change for CYFRA 21-1 (2.1 μg/l) and TPA
(131 U/l), but were different for TPS (237 U/l). In
benign gynaecological disorders the cut off values
were almost the double for all 3 markers as compared
with the healthy persons. In patients with mastopathia
the CYFRA 21-1 values were very low (cut off: 1.3
μg/l), whereas TPA and TPS were increased (TPA:
243 U/l, TPS: 226 U/l). Benign urological diseases
only slightly influenced all markers, whereas renal
failure was combined with a clear increase of CYFRA
21-1 (cut off: 7.2 μβ/l), TPA (cut off: 243 U/l) and
TPS (cut off: 404 U/l), probably due to the fact that
cytokeratin fragments are eliminated by the renal
pathway and therefore accumulate in renal failure.
The highest influence, especially on the TPA and TPS
concentrations, was caused by benign disorders of the
gastrointestinal tract: TPA (cut off: 713 U/l) and
moreover TPS (cut off: 2021 U/l); CYFRA 21-1
showed slightly elevated levels (cut off: 5.2 μg/l).
In lung cancer, NSE, with a sensitivity of 55%, was
confirmed as the marker of first choice for small cell
lung carcinomas (CYFRA 21-1: 52%, TPA: 52%,
TPS: 32%, CEA: 18%, SCC: 6%).
In non-small cell lung carcinomas, CYFRA 21-1 dis-
criminated with 64% sensitivity at a 95% specificity
better between benign diseases of the lung and lung
carcinomas than TPA (50%), TPS (17%), CEA (33%)
and SCC (19%). Moreover, as demonstrated in table
4, the sensitivity of CYFRA 21-1 correlates clearly
with tumour size and tumour stage.
In adenocarcinomas of the lung, CYFRA 21-1, with
54% true positive test results, showed the highest
sensitivity (also compared with the combined deter-
minations), followed by TPA (40%) and CEA (41%).
TPS (16%) and SCC (5%) showed a very small num-
ber of true positive test results.
In large cell lung carcinomas, CYFRA 21-1 revealed
a sensitivity of 65% (TPA: 41%, CEA: 27%, TPS:
18%). In this case a combination of CYFRA 21-1
and TPA increased sensitivity to 77%. In squamous
cell carcinomas of the lung, the benefit of CYFRA
21-1 versus the other markers became evident with
79% true positive test results (TPA: 62%, CEA: 25%,
SCC: 38%, TPS: 18%). None of the possible com-
bination could improve this good result (tab. 5).
Independent of the histological type, CYFRA 21-1
emerged as a type of "pan-marker" for lung cancer
because of its high overall sensitivity of 61 % in lung
cancer (TPA: 51%, CEA: 28%, TPS: 22%, SCC:
18%, NSE: 19%). From our investigations it is evi-
dent that TPA detects at least partly the same sub-
stance as CYFRA 21-1 (the sensitivities compared
with the markers TPS, CEA, SCC and NSE were
rather high, but not as high as for CYFRA 21-1)
whereas TPS represents a completely different clinical
chemical analyte (lowest number of true positive test
results over the whole investigation). These findings
correspond cleary to the very recent results of the
comparison of the antibodies used in the CYFRA 21-
1, TPA and TPS assay by immunoblotting. These
investigations, presented by Bodenm ller et al. at a
recent symposium on cytokeratins (5), show that TPA
detects mainly cytokeratin 8 and 19 and to a very
small degree cytokeratin 18. Therefore TPA gives the
highest number of true positive test results after CY-
FRA 21-1 (which does not detect cytokeratin 8 and
18, but only 19). TPS detects mainly cytokeratin 18
and to a small extent 8 and 19. This explains the
negligible sensitivities of TPS in lung cancer.
In conclusion, CYFRA 21-1 is superior to the other
cytokeratin markers, TPA and TPS, as a marker of
lung cancer.
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